Optimizing endobronchial ultrasound for molecular analysis. How many passes are needed? - Wikidata - awgldk - TriplyDB

Optimizing endobronchial ultrasound for molecular analysis. How many passes are needed?

Optimizing endobronchial ultrasound for molecular analysis. How many passes are needed?

http://www.wikidata.org/entity/Q53088478

about

Transbronchial lung biopsy and pneumothorax A multifactoral analysis of 1452 patients for smoking sensation. An outpatient lab experience.Understanding local performance data for EBUS-TBNA: insights from an unselected case series at a high volume UK center.Identification of major factors associated with failed clinical molecular oncology testing performed by next generation sequencing (NGS).Comparison of Epidermal Growth Factor Receptor Mutations between Metastatic Lymph Node Diagnosed by EBUS-TBNA and Primary Tumor in Non-Small Cell Lung Cancer High concordance of ALK rearrangement between primary tumor and paired metastatic lymph node in patients with lung adenocarcinoma.Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.Advances in interventional pulmonology.Endobronchial ultrasound-guided transbronchial needle aspiration for non-small cell lung cancer staging.Optimizing tissue sampling for the diagnosis, subtyping, and molecular analysis of lung cancer.Endobronchial ultrasound-guided transbronchial needle aspiration in lung cancer diagnosis and staging.Next-generation sequencing of liquid-based cytology non-small cell lung cancer samples.Diagnostic Value of Convex Probe Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in Mediastinal Tuberculous Lymphadenitis: A Systematic Review and Meta-Analysis.ALK and ROS1 testing on lung cancer cytologic samples: Perspectives.Endobronchial ultrasound-transbronchial needle aspiration for mediastinal staging of non-small cell lung cancer: variability of results and perspectives COST ANALYSIS OF INTRA PROCEDURAL RAPID ON SITE EVALUATION OF CYTOPATHOLOGY WITH ENDOBRONCHIAL ULTRASOUND.Bronchoscopy with endobronchial ultrasound guided transbronchial needle aspiration vs. transthoracic needle aspiration in lung cancer diagnosis and staging.Chinese expert consensus statement on issues related to small specimen sampling of lung cancer.Second-line afatinib administration in an elderly patient with squamous cell carcinoma.Stylet Use Does Not Improve Diagnostic Outcomes in Endobronchial Ultrasonographic Transbronchial Needle Aspiration: A Randomized Clinical Trial.Molecular testing on endobronchial ultrasound (EBUS) fine needle aspirates (FNA): Impact of triage.Reply: Endobronchial Ultrasound-guided Transbronchial Needle Aspiration under General Anesthesia.Next-Generation Sequencing of Endobronchial Ultrasound Transbronchial Needle Aspiration Specimens in Lung Cancer.

P2860

Q26825469-08B9B344-D01C-4EDE-81AE-396CDB612A71 Q33634980-C04DF173-C8DD-4E0E-9ED2-412EA266F3CB Q33766063-DF5B4A97-28F2-40A4-B0DB-839177BE8E6A Q35662768-1BA049B7-F612-44E4-96A3-9AA623B0E2C9 Q36148697-3B7B699B-886D-46E7-84EB-F1CAF0820AE2 Q36948934-E9333E5D-E45E-4B58-B203-804B87F80583 Q37017060-49549C1B-0228-479B-AE18-1DD326244EA5 Q38180727-0CB4396D-84A8-46D4-B9F5-4D70E08DA133 Q38183919-87D5552A-5CBA-4533-985B-FF347DA96D54 Q38258089-0F8FF299-4228-4D24-9807-3C5736CCDC9C Q38286398-12808DFD-0B90-4959-9765-18DD5C5AFB52 Q38376363-EE464114-7F54-4DB8-A9CF-E0D3786171D4 Q38547682-3B9996B0-0EFD-48B2-BAA9-0188661AAC6A Q38651989-F707B43C-94AA-457A-B0FD-31A37357ECD3 Q38730974-80D860C4-B30B-4A1A-B847-DFA3985D45C1 Q40122644-325515CC-3440-41F6-B1FA-514B80AE1720 Q41241594-496AF551-279C-4843-B6DB-27F4B7DC7BBD Q41585672-6A0EF2DE-B11B-439F-AEEA-271D18352723 Q41823165-85630EC5-92CB-424F-8D28-5C310A81926A Q46140163-B9C2C841-507F-4FCB-90A8-A8D1E661F548 Q47611154-FD29840D-B974-4062-8C7A-CDD0870419A5 Q47633050-61003261-3421-48F9-B338-FE156B832A2A Q48004940-234B17B1-AA5C-413A-B2D2-FEBB5BB670EB

P2860

Optimizing endobronchial ultrasound for molecular analysis. How many passes are needed?

http://www.wikidata.org/entity/Q53088478

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Optimizing endobronchial ultrasound for molecular analysis. How many passes are needed?

@en

Optimizing endobronchial ultrasound for molecular analysis. How many passes are needed?

@nl

type

label

Optimizing endobronchial ultrasound for molecular analysis. How many passes are needed?

@en

Optimizing endobronchial ultrasound for molecular analysis. How many passes are needed?

@nl

prefLabel

Optimizing endobronchial ultrasound for molecular analysis. How many passes are needed?

@en

Optimizing endobronchial ultrasound for molecular analysis. How many passes are needed?

@nl

P1433

Q53088478-816EFD6B-937D-41A3-84C5-017E828FE2EC

P1476

Q53088478-23CF59B7-A0F3-42E1-8FB3-2D5823C5F280

P2093

Q53088478-21FC8E86-9C4B-4F4B-957C-9DB2CD2CF430

Q53088478-47320BE2-439E-47D9-8A1B-07072274ABC7

Q53088478-5180947B-7695-4D2C-8E8C-DBB0DF50B0D9

Q53088478-51958C39-A04A-4CE1-8E5D-FB3CEACA83A9

Q53088478-AA35381F-9577-4ED4-A78B-C55BBFEE3729

Q53088478-B49FAFDB-73ED-423E-83A0-3B0CDCC016E9

Q53088478-E114F380-4AD5-46A0-80DD-C1DC5A33B7C9

P2860

Q53088478-03FA3275-4A17-4AB2-956E-4DA45D46EF7B

Q53088478-06F6D318-050E-4C54-AC32-F3C023C413C8

Q53088478-081D425D-8188-47CE-8929-D96D6DE07CE5

Q53088478-0FDC02DB-1185-4713-9ACE-E18DB92B496E

Q53088478-12B121EB-19D8-4B59-8361-A70CC8FA2587

Q53088478-1EF323CE-11A8-4ED0-AAB4-B1E6D36FBF00

Q53088478-2FF1424A-079A-4F4F-8AAD-B2ED91C8BB08

Q53088478-3FC2D3A0-0E7A-4FF7-BB1F-B3F8B5A1C59D

Q53088478-46F3B2FF-64C8-40E6-8EFE-19B723357F30

Q53088478-4ABA8414-52DA-4CDE-8A8E-046465690D53

P304

Q53088478-15A32C0C-AD44-4A77-A89D-388E1EE46098

P31

Q53088478-4563287B-C4F7-4ADA-9839-14509ACA2560

P356

Q53088478-3601E821-3FEA-4F18-BE50-5A027B884C12

P433

Q53088478-2127442B-0D68-4F63-A88A-2CA722D4BFF5

P478

Q53088478-D62D895B-2C55-4C83-8CCD-BB0B704961E4

P50

Q53088478-0243E811-6FF0-414A-AFAB-0E02848A8761

Q53088478-6B63A85C-BF9D-4526-88D1-D49718D80011

P577

Q53088478-E96D2E2F-7982-4464-A0B9-786377574CB1

P698

Q53088478-981D17B3-F38E-43C1-B348-9821E7B0F82D

P356

ANNALSATS.201305-130OC

P1433

Proceedings of the American Thoracic Society

P1476

Optimizing endobronchial ultrasound for molecular analysis. How many passes are needed?

@en

P2093

Hans J Lee

http://www.w3.org/2001/XMLSchema#string

Jason Akulian

http://www.w3.org/2001/XMLSchema#string

Lonny Yarmus

http://www.w3.org/2001/XMLSchema#string

Noah Lechtzin

http://www.w3.org/2001/XMLSchema#string

Paul Zarogoulidis

http://www.w3.org/2001/XMLSchema#string

Syed Z Ali

http://www.w3.org/2001/XMLSchema#string

Vidya Sathiyamoorthy

http://www.w3.org/2001/XMLSchema#string

P2860

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Acquisition and processing of endobronchial ultrasound-guided transbronchial needle aspiration specimens in the era of targeted lung cancer chemotherapy.

A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer.

P304

636-643

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1513/ANNALSATS.201305-130OC

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Christopher Gilbert

David Feller-Kopman

P577

2013-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24079724

http://www.w3.org/2001/XMLSchema#string